glpletter — Page 2

Skin's molecular barriers make peptide patches far harder than researchers admit.

Scientists are engineering patches and energy pulses to deliver peptides through skin.

Needle fear keeps a meaningful share of patients from taking life-sustaining injections they need.

Injectable routes bypass the gut's defenses, but patients quit anyway from needle burden.

Chronic biologic patients skip doses because the needle wears them down, not because it hurts.

How delivery method shapes brain access and real-world adherence to GLP-1 drugs.

The gut destroys ninety percent of the drug before it reaches the bloodstream.

Multiple pathways in heart and blood vessels explain how GLP-1 drugs cut cardiovascular risk.

GLP-1 drugs reduce liver fat and inflammation, but struggle to reverse fibrosis.

GLP-1 drugs reshape sleep architecture through brain circuits most trials never measured.

GLP-1 drugs reduce craving for nicotine and opioids by rewiring the brain's reward circuitry itself.